[go: up one dir, main page]

AR077972A1 - Anticuerpos contra cdcp1 destinados al tratamiento del cancer - Google Patents

Anticuerpos contra cdcp1 destinados al tratamiento del cancer

Info

Publication number
AR077972A1
AR077972A1 ARP100103120A ARP100103120A AR077972A1 AR 077972 A1 AR077972 A1 AR 077972A1 AR P100103120 A ARP100103120 A AR P100103120A AR P100103120 A ARP100103120 A AR P100103120A AR 077972 A1 AR077972 A1 AR 077972A1
Authority
AR
Argentina
Prior art keywords
antibody
intended
antibodies against
cancer treatment
cancer
Prior art date
Application number
ARP100103120A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR077972A1 publication Critical patent/AR077972A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Composicion farmacéutica que comprende el anticuerpo, uso del anticuerpo para la preparacion de un medicamento destinado al tratamiento del cáncer; ácido nucleico codificante del anticuerpo humanizado; vectores de expresion y célula huésped. Reivindicacion 1: Anticuerpo de union específica a CCP1 humana, caracterizado por la union al mismo epítopo que CUB4 (n° de deposito DSM ACC2551) para el tratamiento del cáncer.
ARP100103120A 2009-08-28 2010-08-26 Anticuerpos contra cdcp1 destinados al tratamiento del cancer AR077972A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09011047 2009-08-28

Publications (1)

Publication Number Publication Date
AR077972A1 true AR077972A1 (es) 2011-10-05

Family

ID=41349259

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103120A AR077972A1 (es) 2009-08-28 2010-08-26 Anticuerpos contra cdcp1 destinados al tratamiento del cancer

Country Status (9)

Country Link
US (1) US8883159B2 (es)
EP (1) EP2470206A1 (es)
JP (1) JP5680646B2 (es)
CN (1) CN102481366A (es)
AR (1) AR077972A1 (es)
CA (1) CA2770141A1 (es)
SG (1) SG178881A1 (es)
TW (1) TW201113037A (es)
WO (1) WO2011023390A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140363448A1 (en) * 2012-01-02 2014-12-11 Novartis Ag Cdcp1 and breast cancer
WO2015082446A1 (en) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-cdcp1 antibody and a taxane
WO2018112334A1 (en) 2016-12-16 2018-06-21 Bluefin Biomedicine, Inc. Anti-cub domain-containing protein 1 (cdcp1) antibodies, antibody drug conjugates, and methods of use thereof
US10928391B2 (en) * 2017-06-06 2021-02-23 The Cleveland Clinic Foundation CD318 as a marker for, and CD318 inhibition as a treatment for, autoimmune disease
US11603412B2 (en) 2017-10-25 2023-03-14 The Regents Of The University Of California Antibodies against CDCP1 for the treatment and detection of cancer
US12371507B2 (en) 2018-11-09 2025-07-29 Beth Israel Deaconess Medical Center CDCP1 antibodies and antibody drug conjugates
AU2023286928A1 (en) * 2022-06-20 2025-01-02 Sichuan Huiyu Pharmaceutical Co., Ltd. Antibody and use thereof
KR20240057529A (ko) * 2022-10-24 2024-05-03 주식회사 노벨티노빌리티 신규 항-cdcp1 항체 및 이의 용도
WO2025199124A1 (en) * 2024-03-19 2025-09-25 Tavotek Lab Inc Antibodies targeting cd318 (cdcp1) and uses thereof
WO2025237395A1 (en) * 2024-05-17 2025-11-20 TJ Biopharma (Shanghai) Co., Ltd. Anti-cdcp1 constructs and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
ES2569919T3 (es) 1999-04-09 2016-05-13 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
CN1329061A (zh) 2000-06-19 2002-01-02 上海博德基因开发有限公司 一种新的多肽——人g蛋白亚基9.46和编码这种多肽的多核苷酸
EP1301533A1 (de) 2000-07-07 2003-04-16 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Tumorassoziiertes antigen (b345), gekennzeichnet durch eine aminosäuresequenz wie in seq. id. no. 4
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
DE10242146A1 (de) 2002-09-04 2004-03-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper zur Identifizierung und/oder Isolierung von hämatopoetischen Stammzellen
ATE475708T1 (de) 2003-01-22 2010-08-15 Glycart Biotechnology Ag Fusionskonstrukte und deren verwendung zur produktion von antikörpern mit erhöhter fc rezeptor bindungsaffinität und effektorfunktion
WO2004074481A1 (en) 2003-02-19 2004-09-02 Novartis Ag Glycorpotein antigen sima135 expressed in metastatic human tumor cells
WO2005011735A1 (en) 2003-07-29 2005-02-10 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with enhanced effector function
JP2007503206A (ja) 2003-08-22 2007-02-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 変更されたエフェクター機能を有する改良された抗体およびその抗体を産生する方法
AU2004273791A1 (en) 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
GB0324656D0 (en) 2003-10-22 2003-11-26 Celltech R&D Ltd A protein involved in ovarian cancer
ES2708095T3 (es) 2003-11-05 2019-04-08 Roche Glycart Ag Anticuerpos de CD20 con afinidad de unión a receptor de Fc y función efectora incrementadas
US20080008719A1 (en) * 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
JP5315489B2 (ja) 2005-04-26 2013-10-16 アール クレア アンド カンパニー エフェクター機能が増強されたヒトＩｇＧ抗体を作製する方法
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
US20070031419A1 (en) 2005-06-30 2007-02-08 Applera Corporation Methods and compositions for treating diseases targeting CDCP1
KR101379568B1 (ko) 2005-08-26 2014-04-08 로슈 글리카트 아게 변형된 세포 신호 활성을 가진 개질된 항원 결합 분자
JP2007112734A (ja) 2005-10-19 2007-05-10 Chugai Pharmaceut Co Ltd 抗ｃｄｃｐ１抗体を含有する癌細胞増殖抑制剤
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
TWI412375B (zh) * 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體

Also Published As

Publication number Publication date
US20110070246A1 (en) 2011-03-24
CA2770141A1 (en) 2011-03-03
CN102481366A (zh) 2012-05-30
JP5680646B2 (ja) 2015-03-04
EP2470206A1 (en) 2012-07-04
TW201113037A (en) 2011-04-16
SG178881A1 (en) 2012-04-27
WO2011023390A1 (en) 2011-03-03
US8883159B2 (en) 2014-11-11
JP2013502905A (ja) 2013-01-31

Similar Documents

Publication Publication Date Title
AR077972A1 (es) Anticuerpos contra cdcp1 destinados al tratamiento del cancer
MX2012002458A (es) Anticuerpos anti-cdcp1 humanizados.
CL2012003054A1 (es) Anticuerpos contra la angiopoyetina 2 humana (ang-2); composicion farmaceutica que contiene dicho anticuerpo; uso del anticuerpo para preparar medicamento destinado a la prevencion de metastasis; acido nucleico que codifica dicho anticuerpo; vector de expresión.
CL2017001580A1 (es) Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped.
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
MX2015010836A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno anti egfrviii humanizado.
JOP20210044A1 (ar) الأجسام المضادة لـ cd38
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
AR074563A1 (es) Anticuerpos anti ligando 1 de muerte programada (anti-pd-l1) y su uso para mejorar la funcion de las celulas t
MX348578B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
AR073425A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina
NZ607969A (en) Cd33 binding agents
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
BR112012018951B8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
MX351682B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
MX2010009190A (es) Anticuerpos anti-c5ar humanizados.
AR101669A1 (es) Constructos de anticuerpos para cdh19 y cd3
CL2011002756A1 (es) Anticuerpo que se enlaza a la proteina del complemento c3b humana o de cinomolgo; composicion farmaceutica, acido nucleico, vector y celula huesped que comprenden dicho anticuerpo; uso para tratar degeneracion macular relacionada con la edad.
CO6612271A2 (es) Anticuerpos anti-cd40
BR112012021327A2 (pt) anticorpo monoclonal anti-her2 completamente humano, método de preparação e uso do mesmo.
CL2016000438A1 (es) Anticuerpos humanizados que se unen específicamente al receptor del factor estimulante de colonias 1 (csf-1r); ácidos nucleicos; vectores de expresión, células huéspedes; procesos de producción; composiciones farmacéuticas; usos y métodos de tratamiento terapéutico para el tratamiento del cáncer y de la enfermedad fibrótica

Legal Events

Date Code Title Description
FB Suspension of granting procedure